There’s a good reason why the FDA awarded multiple breakthrough therapy designations to psilocybin for depression that is resistant to treatment and major depressive disorders.
The Center Square by Christina Lengyel
The mental health professionals are discovering new ways to use old medications.
Legislators are reconsidering their categorization of magic mushrooms due to recent research that shows the effectiveness of the active ingredient, psilocybin.
Veterans who suffer from post-traumatic disorder (or PTSD) have been helped by psychedelics.
Ryan Gardill is a Marine Corps veteran, a firefighter, and the president of the Manheim Township Professional Firefighters Association. He also serves as a peer-support coordinator. Gardill shared his views at a House Democratic Policy Committee meeting. In his field, he said that suicides are more common than line-of duty deaths.
Gardill said, “You’re right, I have seen this problem in everyone who has gone through it.” Gardill said, “The therapy worked, but I felt it focused too much on the past, not enough on the present.”
Gardill shared his experience of surviving suicide, but was not alone. Brett Waters is an attorney, founder of the advocacy group Reason for Hope and he recalled his positive experience in college with psilocybin, after his mother committed suicide.
Waters stated that the FDA had given psilocybin several breakthrough therapy designations, including for major depression disorder and treatment-resistant depressive illness. Waters said that psilocybin may provide a rapid, durable and robust relief.
Waters makes reference to the U.S. Food and Drug Administration.
The use of psychoactive drugs has been studied for decades, but the early adopters have seen their progress slowed down after these drugs were associated with the counterculture movement of the 1960s.
Renewing interest, in the 21st-century, has resulted in clinical trials for conditions including PTSD and anxiety. The results are encouraging.
In 38 of the states that have legalized medical marijuana, legislators are generally willing to revisit past policies in light new research. The issue of psychedelics is one that has a lot of bipartisan support.
In 2024 state Sen. Tracy Pennycuick, R-Red Hill, herself a veteran, announced her intention to introduce a bill that would expand the state’s Right-to-Try Act to veterans seeking 3,4-methylenedioxymethamphetamine, more commonly known as MDMA, or psilocybin therapy for PTSD. The bill was never introduced.
Mike Schlossberg (D-Allentown) said, however, that his Democratic colleagues lost primaries because they supported the treatment. The congressman asked him how this issue can be de-stigmatized.
Gardill said that when Gardill responds to a home call, he doesn’t check to see if the person is a Republican. Because we’re nonpartisan and bipartisan, when we answer calls, we hope to find a solution that is also bipartisan.
Ketamine is a common anesthetic that has been FDA approved for depression resistant to treatment. It’s administered under clinical supervision in therapy offices. Although psychiatrists warn that it is an imperfect treatment, as with most other treatments, Ketamine has been shown to work for mental health issues.
Dr. Michael Thase is a psychiatrist who has specialized in depression resistant to treatments. He said that psychoactive drugs such as psilocybin and ketamine usually show their effectiveness within just a few weeks of treatment. Treatments for ketamine may need to be repeated, while the benefits of psilocybin can last as long as six months.
Still, neither of these drugs is considered first-resort. Most patients have to go through a litany of therapies and pharmaceuticals like selective serotonin reuptake inhibitors – known also as SSRIs – before doctors determine that they have a resistant form of the disease.
Compass Pathways has produced a synthetic version psilocybin. The company says that when the FDA approves their drug, it wants Pennsylvanians to have access. Pennsylvania’s trigger law does not reschedule drug schedules in the wake of federal change. Echoing Waters they advocated before the panel to update the state’s regulation systems so that patients can use new medicines whenever they are made available.
They also said that expanded mental healthcare would affect the economy. Thase highlighted increased unemployment among depression sufferers as well as an increase in diseases like diabetes, obesity and heart disease.
Treating mental health and depression is beneficial for all types of illnesses. Long-term, this reduces the cost of health care. Orr stated that both insurance companies as well as governments do not take into account this. “They don’t look at the long-term effects of increasing efficiency at the workplace, at the home, less accidents, less divorces—none of this. The health of your mind is important for a healthy physical body.
The Center Square published this article first.
MEDCAN24 could not exist without readers’ support. Please consider making a Patreon monthly pledge if you depend on our cannabis journalism for information.
